Reduction in size of a thyrotropin-secreting pituitary adenoma treated with octreotide acetate (somatostatin analog)

Eunjig Lee, K. R. Kim, Sungkil Lim, H. C. Lee, D. I. Kim, S. H. Kim, K. B. Huh

Research output: Contribution to journalArticle

13 Citations (Scopus)


We present a 55-year-old female with a thyrotropin (TSH)-secreting pituitary adenoma who had been treated with somatostatin analog octreotide acetate (SMS 201-995) for 4 months. Subcutaneous injection of 100 μg octreotide acetate twice daily resulted in significant reduction of the TSH, thyroid hormone, and tumor size. During the treatment, there was no evidence of any side effects. We may conclude that octreotide acetate administration is an effective treatment in patients with TSH-secreting pituitary adenoma for suppressing TSH hypersecretion and reducing the size of the tumor.

Original languageEnglish
Pages (from-to)109-112
Number of pages4
JournalEuropean Journal of Endocrinology
Issue number1
Publication statusPublished - 1994 Jan 1


All Science Journal Classification (ASJC) codes

  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Cite this